Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Daniel DiPrimeo"'
Autor:
Ghassan K. Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A. Piha-Paul, Joseph S. Light, Scott Sherrin, Amin Yaqubie, Alison Clemens O’Neill, James J. Harding, Raed Al-Rajabi, Crystal S. Denlinger, Pablo Cano, Albert S. Cornelius, Eileen M. O'Reilly, Daniel DiPrimeo, Lisa D. Eli, John D. Gordan, David B. Solit
Publikováno v:
Liver Cancer, Pp 1-10 (2024)
Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER tyrosine kinase inhibitor neratinib as monother
Externí odkaz:
https://doaj.org/article/060277f2d7054affa161c9c60698ca95
Autor:
Joanne Bowen, Sofia Braga, Valeria Dal Zotto, John Finnie, Daniel DiPrimeo, Blaire Cooke, Georg F. Bischof, Alvin Wong, Jack A. Di Palma
Publikováno v:
Physiological Reports, Vol 12, Iss 16, Pp n/a-n/a (2024)
Abstract The irreversible pan‐HER tyrosine kinase inhibitor neratinib is approved for patients with HER2‐positive, early‐stage and metastatic breast cancer (BC). Neratinib‐associated diarrhea is the most common reason for early discontinuatio
Externí odkaz:
https://doaj.org/article/4ac23f911fbd43ba915c155b47741514
Autor:
James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos
Externí odkaz:
https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1
Autor:
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A. García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanne McCulloch, Sara A. Hurvitz, Carlos H. Barcenas
Publikováno v:
Breast, Vol 67, Iss , Pp 94-101 (2023)
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation. The phase
Externí odkaz:
https://doaj.org/article/59dce946fa4342e6b9fbbf464f2e5a40
Autor:
Frankie A. Holmes, Beverly Moy, Suzette Delaloge, Stephen K.L. Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H. Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Angel Guerrero Zotano, Neelima Denduluri, Debra Patt, Erhan Gokmen, Ira Gore, John W. Smith, Sibylle Loibl, Norikazu Masuda, Zorica Tomašević, Katarina Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martin, Arlene Chan
Publikováno v:
European Journal of Cancer. 184:48-59
ExteNET showed that neratinib, an irreversible pan-HER tyrosine ki- nase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved inva- sive disease-free survival in women with early-stage HER2-positive breast cancer. We rep
Autor:
Cynthia Ma, James Waisman, Adam M. Brufsky, Eddy S. Yang, Hans Wildiers, John P. Crown, Sarina A. Piha-Paul, Jennifer M. Suga, José Ángel García-Sáenz, Valentina Gambardella, Angel Guerrero, Salomon Stemmer, Ron Bose, Tonya Novara-Demgen, Daniel DiPrimeo, Lisa D. Eli, Komal Jhaveri
Publikováno v:
Cancer Research. 83:PD17-01
Background: In the SUMMIT trial, original cohorts of patients with HR+, HER2-negative (locally assessed), HER2-mutant MBC received N alone or N+F, with promising clinical response rates but abbreviated duration. Clinical progression coincided with em
Autor:
James Harding, Sarina Piha-Paul, Ronak Shah, Jessica Murphy, James Cleary, Geoffrey Shapiro, David Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James Ford, Monica Arnedos, Salomon Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael Berger, Lisa Eli, Funda Meric-Bernstam, Komal Jhaveri, David Solit, Ghassan K Abou-Alfa
HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2-mutant tumours. SUMMIT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b700187bbc235ce424c878694ad5b456
https://doi.org/10.21203/rs.3.rs-1576467/v1
https://doi.org/10.21203/rs.3.rs-1576467/v1
Autor:
James J. Harding, Sarina Anne Piha-Paul, Ronak H. Shah, James M. Cleary, David I. Quinn, Irene Brana, Victor Moreno, Mitesh J. Borad, Sherene Loi, Iben Spanggaard, James M. Ford, Daniel DiPrimeo, Michael F. Berger, Lisa DeFazio Eli, Funda Meric-Bernstam, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Journal of Clinical Oncology. 40:4079-4079
4079 Background: HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs) and are associated with poor overall survival (OS) in patients with metastatic disease. HER2 overexpression is associated with an increased risk of disease
Publikováno v:
British Journal of Clinical Pharmacology. 83:554-561
Aims To evaluate the effect of lansoprazole, a proton-pump inhibitor, on the absorption, pharmacokinetics, and safety of neratinib, a pan-HER tyrosine kinase inhibitor, in healthy subjects. Methods This was an open-label, two-period, fixed-sequence s
Autor:
Bowen, Joanne1 joanne.bowen@adelaide.edu.au, Braga, Sofia2, Zotto, Valeria Dal3, Finnie, John4, DiPrimeo, Daniel5, Cooke, Blaire5, Bischof, Georg F.5, Wong, Alvin5, Di Palma, Jack A.6
Publikováno v:
Physiological Reports. Aug2024, Vol. 12 Issue 16, p1-12. 12p.